Search Results
Dec 04, 2025, 08:37 ET Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has entered into an exclusive distribution agreement with Er-Kim İlaç Sanayi ve Ticaret A.Ş. ("Er-Kim"), a leading pharmaceutical
More news about: Citius Oncology, Inc.
Dec 01, 2025, 12:00 ET Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by
More news about: Citius Oncology, Inc.
Nov 25, 2025, 08:00 ET Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it will exhibit at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 6–9, 2025,
More news about: Citius Oncology, Inc.
Nov 21, 2025, 08:37 ET Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
-- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced a deeper collaboration
More news about: Citius Oncology, Inc.
Oct 21, 2025, 16:30 ET Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J., Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products,
More news about: Citius Pharmaceuticals, Inc.
Oct 21, 2025, 08:00 ET Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J., Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products,
More news about: Citius Pharmaceuticals, Inc.
Oct 20, 2025, 08:37 ET Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it has entered into a distribution services agreement with McKesson Corporation (NYSE: MCK), one of the largest pharmaceutical distributors
More news about: Citius Oncology, Inc.
Oct 17, 2025, 17:00 ET Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and Citius Oncology, Inc. (Nasdaq: CTOR) today announced that management will be participating in three investor conferences in October 2025. Citius Pharmaceuticals (Nasdaq: CTXR)
More news about: Citius Pharmaceuticals, Inc.
Oct 16, 2025, 08:47 ET Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it has finalized an exclusive agreement with
More news about: Citius Oncology, Inc.
Sep 10, 2025, 16:30 ET Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced the closing of its previously
More news about: Citius Oncology, Inc.